Adnan, an infant with an exceedingly uncommon genetic form of epilepsy, has previously tried seven different treatments without success. Following extensive genetic testing to determine the source of his ailment, clinicians at King’s College Hospital London – Dubai obtained access to an experimental medication through a compassionate use pathway supported by the Emirates Drug Establishment and the Dubai Health Authority (DHA).
Adnan received his first dose of ABS-1230 on September 14, 2026. His seizures ended within half an hour, according to the medical team that treated him. He was discharged from the hospital on September 21, 2026.
The hospital confirmed that no clinical seizures had been recorded during follow-up assessments up to October 11, 2026, and that the youngster was also making improvement in growth and development. The hospital also confirmed that he is still seizure-free. According to the treatment’s creator, Adnan is the world’s youngest child to receive ABS-1230 and just the second infant to be administered the experimental medication.
The child’s seizures began within days after birth and got more severe and frequent despite treatment. After standard anti-seizure medications failed to produce the expected results, the medical team used whole-genome sequencing to uncover a disease-causing genetic mutation and investigate therapy options aimed at the molecular process underlying the disorder.
Also Read:
Sphie Vancaeneghem On Customer Experience And Hospitality Industry Trends
